Developing and testing a web-based platform for antiretroviral therapy (ART) adherence support among adolescents and young adults (AYA) living with HIV

PEC innovation Pub Date : 2024-02-12 DOI:10.1016/j.pecinn.2024.100263

Ann-Margaret Dunn Navarra , Maurade Gormley , Eva Liang , Claire Loughran , Allison Vorderstrasse , David R. Garcia , Michael G. Rosenberg , Jason Fletcher , Lloyd A. Goldsamt

{"title":"Developing and testing a web-based platform for antiretroviral therapy (ART) adherence support among adolescents and young adults (AYA) living with HIV","authors":"Ann-Margaret Dunn Navarra , Maurade Gormley , Eva Liang , Claire Loughran , Allison Vorderstrasse , David R. Garcia , Michael G. Rosenberg , Jason Fletcher , Lloyd A. Goldsamt","doi":"10.1016/j.pecinn.2024.100263","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Describe the development and testing of a web-based platform for antiretroviral treatment (ART) adherence support among HIV+ adolescents and young adults (AYA) in a randomized controlled trial (RCT).</p></div><div><h3>Methods</h3><p>A seven-member multi-disciplinary team operationalized the flat, password protected, web-based platform. Manualized protocols guided the objectives and content for each of the eight web-based sessions. Team members evaluated usability and content validity. Client satisfaction and perceived ease of use was evaluated with the first ten HIV+ AYA participants.</p></div><div><h3>Results</h3><p>The web-based platform was developed, evaluated, refined, implemented and pilot tested between September 2020 to April 2022. Usability was rated as high; the evaluation of content validity showed an excellent fit between session content and objectives. HIV+ AYA participants (mean age = 24.2 years) were satisfied with the quality, type, and amount of support/education received, and found the platform easy to use, operate, and navigate. Average time spent per session was 6.5 min.</p></div><div><h3>Conclusion</h3><p>Findings support the usability, validity, acceptability, and feasibility of this web-based platform for ART adherence support among HIV+ AYA.</p></div><div><h3>Innovation</h3><p>Our research and findings are responsive to research gaps and the need for transparency in the methodological development and testing of web-based control arms for ART adherence support among HIV+ AYA.</p></div>","PeriodicalId":74407,"journal":{"name":"PEC innovation","volume":"4 ","pages":"Article 100263"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772628224000116/pdfft?md5=11f6660a38c7f5987ba1117d00951e8c&pid=1-s2.0-S2772628224000116-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PEC innovation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772628224000116","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Describe the development and testing of a web-based platform for antiretroviral treatment (ART) adherence support among HIV+ adolescents and young adults (AYA) in a randomized controlled trial (RCT).

Methods

A seven-member multi-disciplinary team operationalized the flat, password protected, web-based platform. Manualized protocols guided the objectives and content for each of the eight web-based sessions. Team members evaluated usability and content validity. Client satisfaction and perceived ease of use was evaluated with the first ten HIV+ AYA participants.

Results

The web-based platform was developed, evaluated, refined, implemented and pilot tested between September 2020 to April 2022. Usability was rated as high; the evaluation of content validity showed an excellent fit between session content and objectives. HIV+ AYA participants (mean age = 24.2 years) were satisfied with the quality, type, and amount of support/education received, and found the platform easy to use, operate, and navigate. Average time spent per session was 6.5 min.

Conclusion

Findings support the usability, validity, acceptability, and feasibility of this web-based platform for ART adherence support among HIV+ AYA.

Innovation

Our research and findings are responsive to research gaps and the need for transparency in the methodological development and testing of web-based control arms for ART adherence support among HIV+ AYA.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

开发和测试一个基于网络的平台，为感染艾滋病毒的青少年和年轻成人提供抗逆转录病毒疗法坚持治疗的支持

目的描述在随机对照试验（RCT）中开发和测试基于网络的抗逆转录病毒治疗（ART）支持平台，为 HIV+ 青少年和年轻成人（AYA）提供抗逆转录病毒治疗（ART）依从性支持的情况。手册化的协议为八个网络课程的目标和内容提供了指导。团队成员对可用性和内容有效性进行了评估。在 2020 年 9 月至 2022 年 4 月期间，对基于网络的平台进行了开发、评估、改进、实施和试点测试。可用性被评为很高；内容有效性评估显示，课程内容与目标之间非常契合。HIV+ 青少年参与者（平均年龄 = 24.2 岁）对所获得的支持/教育的质量、类型和数量表示满意，并认为该平台易于使用、操作和浏览。创新我们的研究和发现是对研究差距的回应，也是对基于网络的抗逆转录病毒疗法支持方法开发和测试的透明度需求的回应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊